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Effort-related decision making tasks in animals can model motivational symptoms in 
humans, which are a set of symptoms spanning a multitude of neuropsychiatric disorders, such as 
major depressive disorder and the negative symptoms of schizophrenia. The present studies 
aimed to evaluate the effort-related effects of the Val158Met polymorphism of human catechol-
methyltransferase (COMT), by testing mice carrying either the human COMT Val (n=8) or Met 
allele (n=8) with Wild-Type control mice (n=15) by using concurrent FR2 and FR4/pellet choice 
tasks in a touchscreen operant conditioning apparatus. The Val158Met polymorphism has been 
repeatedly associated with neuropsychiatric disorders, and the Val allele has been associated 
with negative symptoms of schizophrenia. Additionally, the effort-related effects of the 
dopamine D2 antagonist, haloperidol, a drug used to treat positive symptoms of schizophrenia, 
but often inducing motivational side effects, was assessed in these transgenic mice. Haloperidol 
(0.05-0.15 mg/kg IP) decreased selection of the high effort/high reward option by reducing panel 
pressing across all genetic groups for both fixed ratio tasks. Furthermore, with the human COMT 
Val allele had significantly reduced panel pressing compared to Wild-Type mice. This study 
further validates the role of dopaminergic transmission in effort-related decision making, and 










The public health impact of diseases and psychiatric disorders with motivational deficits, 
such as major depressive disorder (MDD), schizophrenia, cancers, Parkinson’s (Nunes et al. 2014; 
Salamone & Correa 2012; Dantzer et al. 2012) have grown over time (Maes et al. 2009), and it has 
become apparent that improving the quality of life for these patients requires further exploration 
of the pathophysiology of motivational symptoms. Motivational symptoms, including 
psychomotor retardation, fatigue, and anergia, are disabling and are related to problems with social 
function, employment, and treatment response (Stahl 2002; Yohn et al. 2016). MDD is the fourth 
leading cause of disability worldwide (Maes et al. 2009). However, the most common course of 
treatment for MDD, selective serotonin reuptake-inhibitors (SSRIs), do not alleviate motivational 
symptoms. Approximately 30 – 40% of patients in one study were not responsive to a sufficient 
dose and duration of SSRI/SNRI treatment (Trivedi et al. 2006). Despite decades of research, the 
underlying causes of depression and related disorders is still poorly understood, and the treatment 
of motivational dysfunction needs to be improved.  
Current animal models of motivational symptoms include measures of effort-related 
choice behavior, such as operant tasks (Nunes et al. 2014; Randall et al. 2012) and T-maze 
procedures (Salamone et al. 1994; Pardo et al. 2012; Mott et al. 2009). In rodents, effort-related 
decision making tasks provide a choice between a more valued reinforcer that can only be 
obtained by a high degree of effort versus a low effort/low reward option (Salamone & Correa 
2012; Salamone et al. 2007). Human studies of effort-related decision making demonstrated that 
patients with MDD (Treadway et al. 2012) and schizophrenics with a high preponderance of 
negative symptoms (Gold et al. 2013; Barch et al. 2014; Farvaha et al. 2013; Treadway et al. 
2015) have reduced selection of high effort/high reward options.  
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Motivational symptoms and effort-related choice behavior are controlled by neuronal 
circuits involving mesolimbic and striatal dopamine (Salamone & Correa 2012; Salamone et al. 
1997, 2007). Past research has shown that depletion or antagonism of mesolimbic dopamine, 
regardless of the task used, shifts choice behavior by decreasing selection of the high effort 
option and increasing selection of the lower effort alternative (Randall et al. 2012; Nunes et al. 
2014; Salamone et al. 2014; Yohn et al. 2016; Salamone & Correa 2012). One method used for 
interfering with dopamine transmission is through intraperitoneal injections of a dopamine 
antagonist drug, such as haloperidol. Haloperidol is an antipsychotic drug used to treat positive 
symptoms of schizophrenia (Salamone et al. 2014), but often causes an induction of negative 
symptoms in humans (Artaloytia et al. 2006; Morrens et al. 2008).  The dopamine D2 antagonist 
haloperidol has been studied extensively with effort-related choice procedures and has been 
shown to induce motivational deficits in rats (Salamone et al. 1991, 1994, 1996; Mott et al. 2009; 
Pardo et al. 2012; Randall et al. 2012).  
Catechol-O-methyltransferase (COMT) is an important enzyme in the metabolism of 
catecholamines such as dopamine and norepinephrine (Risbrough et al. 2014). COMT is 
particularly important for the clearance of dopamine from the prefrontal cortex, where COMT 
mRNA is highly expressed and dopamine transporters have low expression; the striatum has 
relatively low COMT expression, but dopamine levels are still effected by the enzyme 
(Matsumoto et al. 2003). The gene encoding for COMT is located on chromosome 22q11.2, and 
has been implicated as a candidate gene for the pathogenesis of neuropsychiatric disorders 
(Risbrough et al. 2014). The human COMT gene is one of the genes deleted in 22q11.2 deletion 
syndrome, a disease in which patients have a high risk for developing multiple psychiatric 
disorders, such as schizophrenia, anxiety and mood disorders (Murphy et al. 1999; Gothelf et al. 
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2005). A single nucleotide polymorphism (SNP) of the human COMT gene, resulting from a 
missense mutation of Valine to Methionine at codon 158, may be associated with a variety of 
psychiatric disorders (Lachman et al. 1996). The Met allele has been shown to cause a 40% 
decrease in enzymatic activity of COMT in the prefrontal cortex, compared to the Val allele 
(Lachman et al. 1996; Chen et al. 2004). The role of the COMT gene in schizophrenia has been 
unclear, with many contradictory findings, and meta-analyses finding no clear association (Hori 
et al. 2014).  Although the COMT gene may not be associated with the whole disease phenotype, 
the gene is being evaluated for its association to specific symptomology. In schizophrenia, the 
Met allele has been associated with mood disorders (Drabant et al., 2006), while the Val allele 
has been linked to negative symptoms (Wang et al. 2010; Pelayo-Teran et al. 2011; Mao et al. 
2016), although there are some conflicting data (Goghari & Sponheim 2008). Therefore, it is 
reasonable to hypothesize that the Val allele could shift effort related choice behavior towards 
the low-effort/low-reward option in an effort-related choice behavior task. 
The present study uses two different operant schedules: concurrent FR2/choice and 
FR4/choice tasks utilizing a touch screen apparatus for mice. Mice were used instead of rats, 
because of the ability to use transgenic mice carrying humanized versions of the COMT gene. 
The study aimed to (1) examine the effects of the COMT Val158Met polymorphism in effort-
related decision-making tasks, and (2) investigate the effects of Val158Met on the pathogenesis 
of motivational deficits through systemic haloperidol administration. It was hypothesized that (1) 
the Val/Val group would show a behavioral shift to the lower-effort alternative as compared to 
the Met/Met and wild type groups and (2) the Val158Met polymorphism would show genetic 
susceptibility to haloperidol-induced motivational deficits through reductions in dopaminergic 
transmission. Furthermore it was expected that haloperidol would not improve selection of the 
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high-effort panel pressing in Val/Val animals because typical antipsychotics such has haloperidol 
generally fail to improve negative symptoms, and in fact tend to exacerbate them (Morrens et al., 
2008). 
 
2. Materials and Methods 
2.1 Animals 
31 adult male mice of mixed S129 and C57BL6J background (Jackson Laboratories, Bar 
Harbor, ME) were purchased at four to five weeks of age and housed separately at 23° with 12-h 
light/dark cycles (lights on at 0:700 h). There were 15 wild-type mice, 8 Val 
(https://www.jax.org/strain/027990) and 8 Met (https://www.jax.org/strain/027993). Mice were 
left undisturbed for seven days following arrival to allow habituation to the environment before 
introducing human handling. Mice weighed 20-30 g at the beginning of the study, and were 
initially food deprived to 85% of their free-feeding body weight for training. Mice were fed 
supplemental chow to maintain weight throughout the study, with water available ad libitum in the 
home cages. Despite food restriction, mice were allowed modest weight gain throughout the 
experiment. All animal protocols were approved by the University of Connecticut Institutional 
Animal Care and Use Committee, and followed NIH guidelines.   
2.2 Pharmacological Agents and Dose Selection 
 Haloperidol was obtained from (Sigma-Aldrich) and was dissolved in a stock solution of 
0.3% tartaric acid solution and then diluted with physiological saline; saline also served as the 
vehicle control. The doses of haloperidol were selected based on pilot studies conducted on mice 
with a S129 background to determine if the dose range used would induce motivational deficits. 
Haloperidol was administered intraperitoneally (IP). 
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2.3 Apparatus  
All experiments and training were performed in standard mouse Bussey-Saksida 
touchscreen chambers (Campden Instruments Ltd., Loughborough, UK; Heath et al. 2015). The 
chamber consisted of Fiberglas trapezoidal walls opening to a touchscreen, with a stainless steel 
holed floor with a removable tray underneath. The touchscreen measured 12.1 inches with a 800 
x 600 resolution screen. There are infrared (IR) beam arrays located 5 mm away from the touch 
screen to ensure that the mice do not have to apply pressure to have a detected response. Across 
from the touchscreen is a reward liquid dispenser, attached to a pump, which would deliver 20 μL 
of milkshake (Strawberry Ensure) reward for the correct amount of touchscreen presses. An LED 
would light up upon delivery of award to cue the mouse to collect delivery, and would turn off 
after reward collection. Additionally, during reward delivery, the touchscreen would turn off until 
the reward was collected. These touchscreen operant chambers are each housed within sound-
attenuating chambers equipped with fans to minimize background noise and offer ventilation.  
2.4 Behavioral Procedures 
 For two days preceding the start of behavioral training, a small dish containing the liquid 
reward (Strawberry Ensure) used in the concurrent fixed ratio/pellet choice procedure was 
introduced to each cage to minimize neophobia (Horner et al. 2013). First, mice were trained on a 
magazine training/continuous reinforcement schedule, in which 20 μL of milkshake was delivered 
every 30 seconds, to train them to obtain the reward from the liquid dispenser. Any panel presses 
during magazine training reset the time and delivered 60 μL of milkshake. Second, mice were 
trained on an FR1 schedule, in which one panel press would equate to delivery of reward, for thirty 
minute sessions, 5 days a week, with a touchscreen panel near the floor, to train the mice to press 
the touch screen for a reward. Third, the touch screen panel was raised on the FR1 schedule, to 
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make the task more difficult. The schedule was then raised to FR2 or FR4 and mice were trained 
until they reached baseline levels of panel pressing (panel presses did not vary very much for each 
individual mice for a week). Finally, mice were trained on the concurrent FR2/pellet choice or 
FR4/pellet choice procedure, in which pre-weighed amounts of 45 mg pellets (Bio-serv, 
Frenchtown, NJ), which typically weighed around 6 g in total, were concurrently available in the 
touchscreen chamber during the session (30 minutes). Pellets were put in a small Petri dish, on the 
bottom of the touchscreen chamber, between the touchscreen and the liquid dispenser. Therefore, 
mice were given the choice of a low-effort option: consuming the less-preferred pellets, or the 
high-effort/high-reward option: panel pressing for liquid reward. The mice were loaded into their 
touchscreen chambers, the soundproof box was shut, and the fixed ratio program was started using 
the computer program, Whisker Server. At the end of the 30-minute session, mice were removed 
from the touchscreen chamber, panel pressing was recorded from the program, ABET II Touch, 
and the amount of pellets consumed was calculated from weighing the pellets left in the petri dish 
and spillage left in the touchscreen chamber’s removable tray. The same groups of mice were used 
for both experiments.  
2.5 Experimental Procedures 
On drug test days, all animals (n=31) received IP injections of the following doses of 
haloperidol; saline vehicle, 0.05, 0.10, 0.15 mg/kg. This experiment used a within-groups design, 
with all mice receiving all drug treatments in a random varied order (one treatment per week). 
Baseline training, or non-drug, sessions were conducted four additional days per week, and 
behavioral performance on these days was unaffected by the previous injections. All injections 
were given 50 minutes before the beginning of the testing session. Mice were then put into their 
respective, prepared, touchscreen chambers, the soundproof box was closed, and the FR2 or FR4 
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schedule was loaded and started on the computer program ABET II Touch. At the end of the 30-
minute session, mice were removed from the operant box, panel pressing was recorded, and the 
amount of pellets consumed was calculated from weighing the pellets and spillage left in the 
touchscreen chamber. Baseline, or nondrug, training sessions were conducted 4 days per week. 
Drug administration and testing was completed on the fourth day. Half the animals were on an 
FR2 schedule while the other half were on an FR4 schedule. All doses were completed for every 
animal, to complete the first part of the experiment. Then, the mice were switched to the other 
fixed ratio schedule they had previously not been on, trained on that new schedule, and the 
experiment was repeated with all drug doses in a within group design. Therefore, all animals had 
been tested with all doses of drug on both a concurrent FR2/pellet choice and FR4/pellet choice 
procedure.  
2.6 Statistical Analyses 
Number of panel presses and gram quantity of pellet intake from the thirty-minute sessions 
in experiments 1-2 were analyzed with repeated measures of analysis of variance (ANOVA), using 
the computer program SPSS. A 3 x 4 factorial ANOVA was used, with a between-subjects factor 
of gene group, and a within-subject factor of the drug treatment. Planned comparisons were made 
with the overall error term to compare the haloperidol treatment to the vehicle control group.  
 
3. Results 
3.1 Experiment 1: Effects of systemic administration of haloperidol on concurrent FR2/pellet 




Figure 1. Effect of haloperidol (HAL) on FR2 panel pressing for three COMT variant groups 
[WT group (n=16), VAL group (n=8), and MET group (n=8)]. Mean (± SEM) number of 
panel presses after treatment with vehicle (VEH) and various doses of HAL. *p < 0.05, 
different from WT; +p < 0.05, different from vehicle treatment for all gene groups 
 
Figure 2. Effect of haloperidol (HAL) on FR2 pellet intake for three COMT variant groups 
[WT group (n=16), VAL group (n=8), and MET group (n=8)]. Mean (± SEM) pellet intake 
after treatment with vehicle (VEH) and various doses of HAL. There were no overall 
significant effects for HAL or COMT gene group on pellet intake for the concurrent 







The effects of haloperidol administration on panel pressing by COMT gene group is shown 
in Figure 1. There was an overall significant effect of haloperidol on panel pressing for the 
concurrent FR2/pellet choice procedure, F(3,84)=5.300, p < 0.05. Post hoc comparisons were 
conducted across gene groups, and showed that panel pressing was suppressed by 0.05, 0.10, and 
0.15 mg/kg HAL compared to vehicle (p<0.05). Repeated measures ANOVA of between subjects 
effects revealed that there was an overall significant effect of COMT gene group on panel pressing 
for the concurrent FR2/pellet choice procedure, F(2,28)=3.921. There was no significant effect of 
the haloperidol dose x gene group interaction. The effects of haloperidol administration on pellet 
intake by COMT gene group is shown in Figure 2. The overall effects of haloperidol, COMT gene 
group, and the Haloperidol x gene group interaction on pellet intake were not significant.  
3.2 Experiment 2: Effects of systemic administration of haloperidol on concurrent FR4/pellet 
choice procedure in wild type and humanized mice carrying COMT158 Met/Val alleles. 
 
Figure 3. Effect of haloperidol (HAL) on FR4 panel pressing for three COMT variant groups 
[WT group (n=16), VAL group (n=8), and MET group (n=8)]. Mean (± SEM) number of 
panel presses after treatment with vehicle (VEH) and various doses of HAL. *p < 0.05, 







Figure 4. Effect of haloperidol (HAL) on FR4 pellet intake for three COMT variant groups 
[WT group (n=16), VAL group (n=8), and MET group (n=8)]. Mean (± SEM) pellet intake 
after treatment with vehicle (VEH) and various doses of HAL. There was no overall 
significant effect of HAL or COMT gene group on pellet intake for the concurrent FR4/pellet 
choice task.  
The effect of haloperidol administration on panel pressing by COMT gene group is shown in 
Figure 3. There was an overall significant effect of haloperidol on panel pressing for the concurrent 
FR4/pellet choice procedure, F(3,84)=16.525, p < 0.001. Post hoc comparisons were conducted 
across gene groups, and showed that panel pressing was suppressed by 0.05, 0.10, and 0.15 mg/kg 
HAL compared to vehicle (p<0.05). Repeated measures ANOVA of between subjects effects 
revealed that there was an overall significant effect of COMT gene group on panel pressing, 
F(2,28)=3.895, p > 0.05. The effect of haloperidol administration on pellet intake by COMT gene 
group is shown in Figure 4. There was no significant effect of the haloperidol dose x gene group 
interaction. The overall effects of haloperidol, COMT gene group, and the haloperidol x gene 





The present study investigated the effects of the COMT Val158Met polymorphism on its 
own and with pharmacological manipulations on effort-related motivational symptoms in 
transgenic mice. In the past, the dopamine D2 antagonist, haloperidol, was shown to effort-
related decision making in rodents by shifting behavior from the high-effort/high-reward option 
to the low-effort/low-reward option. This drug’s effects on effort-related decision making has 
been extensively validated with rats (Salamone et al. 1991, 1994, 1996; Mott et al. 2009; Randall 
et al. 2012), and more recently has been studied in mice (Pardo et al. 2012).  The present study 
demonstrated that haloperidol significantly reduced panel pressing for all genetic groups for both 
FR2 and FR4 schedules. Doses of haloperidol that clearly affect panel pressing appear to have 
little effect on pellet intake, indicating that all types of food-related behaviors were not equally 
affected by dopamine antagonism. This further validates the use of haloperidol to alter effort-
related decision making in mice.  
Effort-related decision making paradigms, such as the touchscreen apparatus for mice, could 
be useful as animal models of motivational symptoms. This is supported by human studies of 
effort-related decision making, which show a shift in effort-related choice behavior from the high 
effort/high reward option towards the low effort-/low reward option in patients with major 
depressive disorder (Treadway et al. 2012) and schizophrenia patients with a preponderance of 
negative symptoms (Gold et al. 2013; Barch et al. 2014; Farvaha et al. 2013; Treadway et al. 
2015). Mice are a useful tool for studying models of human disease, including studies that 
involve using transgenic mice, such as studying the human COMT Val158Met polymorphism. 
An animal model of the Val and Met alleles of the human COMT gene in an effort-related 
decision making task can be helpful for evaluating the link between the Val158Met 
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polymorphism to neuropsychiatric disorders. The experiments demonstrated that the Wild-Type 
group’s panel pressing was significantly higher than the COMT Val allele group panel pressing 
for both FR2 and FR4 schedules. Additionally, as COMT gene variants may affect cognition 
(Hori et al. 2014), it is important to note that there were no significant differences in acquisition 
or the concurrent FR1/pellet choice task, a task which does not highlight differences in effort-
related decision making between groups. The genetic variation of the Val group reduced effort-
related decision making. This is consistent with past studies linking the Val allele to negative 
symptoms of schizophrenia (Wang et al, 2010; Pelayo-Teran et al. 2011; Mao et al. 2016). The 
Val allele has increased enzymatic activity, compared to the Met allele, which has 40% reduced 
enzymatic activity. Thus, a likely mechanism for the effect of the Val allele would be that 
increased enzymatic activity in animals with the Val allele would lead to a reduction in 
mesolimbic dopaminergic transmission, leading to increased motivational symptoms, as would 
occur with negative symptoms of schizophrenia. Perhaps more significant differences between 
the Val and Met groups were not seen because the COMT enzyme mainly works in the prefrontal 
cortex, with an overall reliance on the dopamine transporter, DAT, in the striatum (Risbrough et 
al. 2014; Matsumoto et al. 2003). Mice with a COMT knockout have shown a significant rise in 
levels of prefrontal cortex dopamine, without significant changes of dopamine level in the 
striatum. (Gogos et al. 1998).  
There were several limitations of this study. First, the mixed backgrounds of the mice (S129 
and C57BL6J) may have affected the results, as this adds variability to the background genetics. 
Second, the use of the touchscreen apparatus and the fixed ratio procedures for mice are still 
relatively new, and should be validated with continuing studies using the procedure. These 
experiments showed that in terms of the suppression of panel pressing, the concurrent FR4/pellet 
15 
 
choice procedure yielded the cleanest data compared to the concurrent FR2/pellet choice 
procedure, and will most likely be used in future experiments. Nonetheless, this study validated 
the use of the touchscreen apparatus for studying effort-related decision making in mice. The 
results obtained were similar to the extensively validated studies conducted in rats and mice, 
where haloperidol administration will shift behavior away from the high effort/high reward 
option (Salamone et al. 1991, 1994, 1996; Mott et al. 2009; Pardo et al. 2012; Randall et al. 
2012). This paradigm will be a useful tool in the future for studying other genetic models of 
schizophrenia or major depressive disorder.  
To summarize, haloperidol altered effort-related decision making as measured by the 
concurrent FR2 and FR4/pellet choice procedures in the touchscreen apparatus for mice. 
Additionally, the Val allele of the human COMT gene altered effort-related decision making by 
significantly reducing panel pressing as compared to Wild-Type mice. Together with other 
studies, the present research further validates tests of effort-related decision making in rodents 
for their usefulness as a model of motivational symptoms in humans. This study also further 
supports the compiling evidence that the COMT gene may be involved in the pathogenesis of 
multiple psychiatric disorders, and that the Val allele can be associated with negative symptoms 
of schizophrenia. Additionally, this study falls along the thought process of the Research Domain 
Criterion (RDoC) approach, which prioritizes studying psychiatric symptoms and their 
associated neural circuits, instead of traditional whole diagnostic categories of disorders 
(Cuthbert & Insel 2013). Future directions include further testing the validity of the touchscreen 
apparatus as a test of effort-related decision making in mice. Additionally, further studies will 
include transgenic mouse models of other genes with interact with the dopamine system or 
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COMT, such as dopamine receptor D4 (DRD4) and serotonin transporter promotor region (5-
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